A subsequent phase 1b study (NCT03625505) in patients with wildtype or FLT3-mutated relapsed/refractory AML showed that the combination of venetoclax and gilteritinib was highly active in patients with FLT3-mutated disease, 60% of whom had received one or more prior FLT3 tyrosine kinase inhibitor-based therapies75. This evidence concerns the gene FLT3 and acute myeloid leukemia.